乳腺癌淋巴结放疗大分割未增加患者报告的手臂或臂丛神经症状
本研究基于两个癌症登记处2007-2010年接受淋巴结放疗的pT1-3、pN0-2、M0乳腺癌患者,比较中度大分割(HF,2.25-2.5 Gy/次)与传统分割(CF,≤2 Gy/次)后患者报告的手臂症状。708例可评估患者中,406例接受HFRT,302例接受CFRT,中位随访5.7年。结果显示两组手臂症状和日常生活活动能力评分均值无显著差异,HF组肩部僵硬、手臂活动困难和过顶触及困难报告率更低,手臂肿胀或臂丛神经症状无差异。
要点
- 乳腺癌淋巴结大分割放疗未增加患者报告的手臂症状或功能缺陷
- 传统分割组在某些手臂/肩部功能方面报告更多残疾
- 支持在区域淋巴结靶区采用较短分割方案
核心结论
- 淋巴结大分割放疗与传统分割相比未增加患者报告的手臂症状或功能缺陷。
- 传统分割组患者报告某些手臂/肩部功能残疾更多。
研究设计与样本
- 研究使用两个癌症登记处识别2007至2010年在2个癌症机构接受CT计划淋巴结放疗的pT1-3、pN0-2、M0乳腺癌患者。
- 800例(45.5%)返回完整调查,708例符合条件纳入研究队列。
- 406例(57%)接受HFRT(40 Gy/16次,45 Gy/20次),302例(43%)接受CFRT(45-50 Gy/25次,50.4 Gy/28次)。
主要发现
- 放疗后中位时间间隔为5.7年。
- 诊断时中位年龄HF组59岁,CF组53岁(P<.001)。
- 两组切除淋巴结数(均值n=12)和受累淋巴结数(均值n=3)相似(P=.44)。
- 手臂症状(P=.17)和日常生活活动能力(P=.85)反应总和均值无差异。
临床怎么用
- 对于乳腺癌区域淋巴结需要放疗的患者,可考虑采用中度大分割方案(如40 Gy/16次或45 Gy/20次)以缩短治疗疗程。
- 大分割淋巴结放疗未增加患者报告的手臂症状,且传统分割组在某些肩臂功能方面报告更多残疾。
局限性
- 研究为回顾性队列研究,基于两个癌症登记处,可能存在选择偏倚。
- 仅45.5%的患者返回完整调查,应答偏倚可能影响结果。
- HF组和CF组诊断时中位年龄存在显著差异(P<.001),可能混杂结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether nodal radiation therapy (RT) for breast cancer using modest hypofractionation (HF) with 2.25 to 2.5 Gy per fraction (fx) was associated with increased patient-reported arm symptoms, compared with conventional fractionation (CF) ≤2 Gy/fx. METHODS AND MATERIALS: Two cancer registries were used to identify subjects who received computed tomography-planned nodal RT for pT1-3, pN0-2, M0 breast cancer, from 2007 to 2010 at 2 cancer institutions. After ethics approval, patients were mailed an explanatory letter and the Self-reported Arm Symptom Scale, a validated instrument with 8 questions about arm symptoms and 5 related to activities of daily living. Clinicopathologic characteristics and Self-reported Arm Symptom Scale scores were compared between HF/CF cohorts using nonparametric analysis, χ2 analysis, and multivariate ordinal regression. RESULTS: Of 1759 patients, 800 (45.5%) returned a completed survey. A total of 708 eligible cases formed the study cohort. Of these, 406 (57%) received HFRT (40 Gy/16 fx, 45 Gy/20 fx), and 302 (43%) received CFRT (45-50 Gy/25 fx, 50.4 Gy/28 fx). Median time interval after RT was 5.7 years. Forty-three percent and 75% of patients received breast-conserving surgery and chemotherapy, respectively. Twenty-two percent received breast boost RT, independent of fractionation. Median age at diagnosis was 59 years (HF) and 53 years (CF) (P<.001). The mean numbers of excised (n=12) and involved (n=3) nodes were similar between fractionation cohorts (P=.44), as were the mean sums of responses in arm symptoms (P=.17) and activities of daily living (P=.85). Patients receiving HF reported lower rates of shoulder stiffness (P=.04), trouble moving the arm (P=.02), and difficulty reaching overhead (P<.01) compared with the CF cohort. There was no difference in self-reported arm swelling or symptoms related to brachial plexopathy. CONCLUSIONS: Nodal RT with hypofractionation was not associated with increased patient-reported arm symptoms or functional deficits compared with CF. Subjects treated with CF reported more disability in certain aspects of arm/shoulder function. These data support shorter fractionation utilization when regional nodes are within the therapeutic target.
引用
- Leong N, Truong PT, Tankel K, et al. Hypofractionated Nodal Radiation Therapy for Breast Cancer Was Not Associated With Increased Patient-Reported Arm or Brachial Plexopathy Symptoms. Int J Radiat Oncol Biol Phys. 2017. PMID: 29165285. doi:10.1016/j.ijrobp.2017.07.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。